Expert Interview
Discussing the Development of Cue Biopharma's CUE-401, a Novel TGF-Beta/IL-2 Biologic Designed to Restore Immune Tolerance in Patients with Autoimmune and Inflammatory Diseases
Ticker(s): CUE, NKTRInstitution: Saint Louis University
- Professor and Chair of Molecular Microbiology and Immunology
- Lab studies how immuine cells and cytokines contribute to diseaes such as autoimmunity and cancer
- Recognized leader in Treg biology, industyr collaborator with Cue Biopharma, advising on the development of CUE-401
What are your thoughts on CUE-401?
Added By: ben_adminRank your excitement for CUE-401 on a scale of 1-10
Added By: ben_adminHelp us understand how you reconcile the likely pro-inflammatory effects of the drug on TH17/TH9 cells in a high IL4 IL6 environment.
Added By: bioguru991Was there any data generated in pre-clinical atopic dermatitis models? If not, why not?
Added By: bioguru991Why did CUE stick to the CUE100 and not develop a mutein more biased toward CD25?
Added By: bioguru991Do you have a view on the iTREG methylation? The data you show on the R&D day regarding TSDR Methylation is compelling but it this with iTRegs or All Tregs?
Added By: bioguru991The experiments conducted on effector T-cells which converted 10% into Tregs, were they conducted in high inflammatory environments?
Added By: bioguru991What toxicities do you think CUE401 is seeing at 3mg/kg in NHPs?
Added By: bioguru991Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
